Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
BIO
BIO
NYSE
Health Technology
Medical Specialties
305.96
USD
+4.26
+1.41%
Fermé: 07-22 20:00 (UTC+0)
305.96
USD
+1.34
+0.44%
Pré-marché: 07-23 08:26 (UTC+0)

BIO Statistiques clés

Haut
307.10
Ouverture
301.00
Volume
275.06K
Bas
298.74
Clôture précédente
301.70
Valeur négociée
84.03M
Plus haut 52 sem.
343.12
Vol. relatif
0.897
Amplitude (%)
2.77%
Plus bas 52 sem.
236.73
Taux de rotation
1.27%
Cap. Marché
8.18B
PER (TTM)
50.37
PER (Annuel)
10.978
P/B
1.2
P/S
3.16
Bénéfice par action (BPA)
6.075
Dividende (TTM)
0
Rendement du dividende
0.00%
Actions en circulation
21.70M
Devise
USD

BIO Performance du Prix

7 jour
30 jour
90 jour
180 jour
Depuis le début de l’année
1 An
BIO Répartition des flux monétaires
BIO Volume quotidien des ventes à découvert
BIO Historique du short interest
As of 2026-07-23, the Bio-Rad Laboratories, Inc. (BIO) stock price today is 305.96. Based on this price, the company has a market capitalization of $8.18B, with a P/E ratio of 50.37. On 2026-07-23, BIO traded between 298.74 and 307.10. Today’s stock price is 2.42% above the daily low and 0.37% below the daily high, placing BIO proche de l’extrémité supérieure de its most recent trading range. Trading volume currently stands at 275.06K, compared with an average daily volume of 306.76K. This suggests that trading activity is à peu près conforme à son niveau habituel than usual. Over the past year, Bio-Rad Laboratories, Inc. shares have traded between 236.73 and 343.12. At today’s price, BIO is 29.24% above its 52-week low and 10.83% below its 52-week high.
Nom l'entreprise
Bio-Rad Laboratories, Inc.
Secteur
Health Technology
Industrie
Medical Specialties
Exchanges
NYSE
Nombre d’employés
7,450
Taille du lot
40
Site officiel
Devise
USD
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

BIO FAQ

Recherche
Plus